You are here

Study Finds Over Half of Patients on COX-2 Therapy Take Aspirin

ST. LOUIS, June 14 /PRNewswire-FirstCall/ -- Findings reported in a study published today in the Archives of Internal Medicine found that over half of patients within a predominantly retiree population taking COX-2 anti-inflammatory drugs on a long-term basis were also taking aspirin therapy for its cardio-protective benefit.

Previously published clinical research has shown that using aspirin along with COX-2 therapies can negate the gastrointestinal (GI) benefit of using COX-2's, one of the primary reasons for using these more costly medications.

Researchers at pharmacy benefit manager Express Scripts examined aspirin and other over-the-counter pain reliever use among COX-2 users from a large employer group. In addition to the high rate of aspirin use, half of the aspirin users were taking daily doses of 325mg or more, which is considered higher than necessary for the primary prevention of cardiovascular disease and stroke. Aspirin use has been shown to significantly increase the risk of bleeding in the GI tract, even at low doses, and guidelines state that patients who require aspirin therapy for cardio-protection should use the lowest dose possible.

"These findings have important implications for patient safety and cost," said Emily Cox, PhD, lead author of the study. "For patients needing both cardio-protective and anti-inflammatory therapy, the GI protective effects of a COX-2 agent are lost by taking aspirin and don't justify their higher expense. Patients should ask their physician about changing to another equally effective lower cost non-steroidal anti-inflammatory drug (NSAID) instead of a COX-2 agent."

In patients at high risk for gastric irritation (those over age 65 or with other risk factors), physicians should consider adding therapies such as a generic proton pump inhibitor (PPI) to protect against stomach irritation rather than a COX-2.

"After the decision to use NSAID therapy to treat pain, it is important for physicians to determine which NSAID is most cost-effective and safe for the patient. Balancing the patients' need for the right combination of therapies that provide adequate cardiovascular and GI protection is a complex issue, but one that must be addressed in order to provide high quality, cost-effective healthcare," Cox added.

Source: Express Scripts, Inc.

Recent Headlines

Possible First Treatment Option for Rare Autoimmune Disease of the CNS
New Hematologic Biomarker Test Provides New Approach to Sepsis Triage and Diagnosis
Antibiotics, Statins, and Glucocorticoids All Show Promise
More Than 32% of Patients Responded in Trial
Current, Sole Therapy Not Always Successful/Suitable
Over 1.5 Million Americans Likely to have Wet AMD by 2020 
Potential For Use Against E. Coli, TB, Resistant Bacteria